Arthrosi Therapeutics, a San Diego, CA-based a clinical-stage biotechnology company, raised $75M in Series D funding.
The round was led by Guangrun Health Industry (Hong Kong) Co. Limited and backed by a consortium of investors, including Reichstein Biotech (HK) Co. Limited, a subsidiary of ApicHope Pharmaceuticals.
The company intends to use the funds for the development of AR882, a URAT1 inhibitor.
Led by Litain Yeh, PhD, and CEO, Arthrosi Therapeutics aims to create a treatment option to target uric acid levels and reduce joint damage for people living with gout. AR882 is a potent and selective next-gen URAT1 inhibitor delivered in a once daily immediate release oral capsule. AR882 has the potential to change the treatment paradigm for gout, addressing critical aspects such as serum uric acid (sUA) levels, flares, and tophi reduction.
FinSMEs
12/07/2023